Vivani Medical (NASDAQ: VANI) is making a strategic move by spinning off its neurostimulation division, Cortigent, into an independent, publicly traded company. This bold step allows both Vivani and Cortigent to sharpen their focus—Vivani on pioneering ultra long-acting GLP-1 drug implants for chronic weight management and type 2 diabetes, and Cortigent on neurostimulation technology designed to restore vision and aid stroke recovery.

Why the Spin-Off?

This decision positions Cortigent as a leader in neurotechnology while giving Vivani the freedom to double down on its innovative NanoPortal™ drug implant technology. By operating as separate entities, both companies can pursue tailored strategies, optimize resources, and drive shareholder value.

Cortigent’s Visionary Work

Cortigent, formerly Second Sight Medical Products, has already made history with its Argus® II, the first and only FDA-approved artificial vision device for retinitis pigmentosa. Building on this legacy, Cortigent’s Orion® system, a next-generation cortical visual prosthesis, recently completed a six-year clinical study with promising results. Additionally, the company is exploring neurostimulation for stroke recovery, aiming to help patients regain arm and hand motion.

Vivani’s Future in GLP-1 Therapy

Vivani will now be fully dedicated to revolutionizing chronic disease management with miniature, subdermal GLP-1 implants that provide steady medication release for six months to a year. This could be a game-changer for obesity and type 2 diabetes treatment, offering an alternative to daily or weekly injections.

A Win for Investors and Innovation

The spin-off is expected to unlock value for shareholders, provide greater financial clarity, and enhance each company’s ability to adapt to rapidly evolving markets. As neurostimulation technology gains momentum—thanks in part to innovations from companies like Neuralink—Cortigent is well-positioned to lead the charge.

Meanwhile, Vivani’s next-generation GLP-1 implants could transform the obesity and diabetes treatment landscape, tackling the persistent issue of medication adherence while simplifying patient care.

What’s Next?

Vivani is targeting a Q3 2025 completion for the spin-off, pending regulatory approvals. This move is set to create two powerhouse companies, each tackling critical unmet medical needs in their respective fields.

Stay tuned as Vivani and Cortigent embark on their next chapters, shaping the future of precision medicine and neurotechnology.